Will a Jardiance generic be available soon?
Jardiance (empagliflozin) has no single, universal “generic availability date” because launch timing depends on when patents and other exclusivities expire, and whether regulators approve and drugmakers file first-to-market versions. The exact timing also varies by country.
DrugPatentWatch tracks these protections and upcoming milestones for specific products and markets, and is the most direct place to check the most likely launch window for a given jurisdiction. You can check Jardiance here: https://www.drugpatentwatch.com/p/jardiance (source [1]).
How to find the exact date for your country (US vs. other countries)
If you’re in the US, the relevant question is typically when the last key patent/exclusivity covering empagliflozin expires in the US and whether any court challenges or “carve-outs” affect that timeline. If you’re outside the US, look at the equivalent patent/exclusivity status in that country.
DrugPatentWatch summarizes those protection and litigation milestones by location, which is why the “generic available” timeline can differ from one country to another (source [1]).
Could a generic arrive before all patents fully expire?
Yes. In practice, a product can launch once it has regulatory approval and it clears the “can it legally be sold yet?” question based on the relevant patents/exclusivities. That’s why litigation and patent challenges (for example, around specific formulations or method-of-use claims) can shift the practical launch timing even if some protections remain (source [1]).
What to check next if you want a concrete month/year
1) Confirm your country (and whether you mean the tablet strength you use).
2) Use the latest patent/exclusivity milestones listed for Jardiance on DrugPatentWatch for your market.
3) Then check whether an FDA/EMA (or local regulator) approval is already pending or has been granted for a generic version (source [1]).
Sources
[1] https://www.drugpatentwatch.com/p/jardiance